Cancerworld Magazine
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
SUBSCRIBE FOR FREE
Facebook
Twitter
LinkedIn
Cancerworld Magazine
Cancerworld Magazine
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
Cancerworld Magazine > News > Preclinical model identifies predictors of checkpoint inhibitor response
  • News

Preclinical model identifies predictors of checkpoint inhibitor response

  • 22 September 2020
  • Janet Fricker
Preclinical model identifies predictors of checkpoint inhibitor response
Total
0
Shares
0
0
0
0
0

A study published in PNAS (Chen IX, et al. PNAS 2020) of a new mouse model has enabled the identification of distinct gene signatures that distinguish responders from non-responders to immune checkpoint blockade (ICB).

“Our findings provide a general approach for investigating mechanisms of resistance to ICB and identifying predictive biomarkers of response,” write the authors Rakesh Jain, Meromit Singer, and colleagues from Harvard Medical School, Boston, MA.

Although ICB has been approved by the FDA in more than 20 indications, only a subset of patients have been found to derive any clinical benefit. For example, more than 75% of patients with breast cancer who received either anti-PD-1 or anti-PD-L1 treatment did not show any objective response. Therefore, there is intense interest in identifying and developing predictive biomarkers of ICB response.

In the current study, the investigators report on a new bilateral mouse tumour implantation model permitting both resection of the tumour as well as evaluation of treatment response. This is the first time this model has been used in breast cancer “to assess the entire immune compartment within the tumour microenvironment in a resection and response-type model”, explains Rakesh Jain. For the study, bilateral breast cancer tumours were implanted into the mammary fat pads of mice, and the animals were treated with an anti-PD1 antibody or a control IgG antibody. A tumour on one side was removed to allow for evaluation of the tumour microenvironment, while the tumour on the other side was kept in situ to monitor treatment response and enable the mouse to be identified as a responder or a non-responder.

Results showed that responder mice had higher levels of CD8+ T-cell infiltration in the tumour microenvironment and that transcriptomic analysis of CD8+ T cells revealed distinct gene signatures that distinguished responders from non-responders. Furthermore, these gene signatures for responders and non-responders correlated significantly with responder and non-responder gene signatures derived from melanoma patients who were treated with ICB, as well as overall survival in breast cancer patients treated with ICB.
“Based on these analyses and our observation that patient survival rates significantly associated with our generated responder and non-responder signatures, we envision that future studies could construct a classifier that utilizes distinct attributes of these human-adjusted signatures to assist with patient diagnostic and treatment decisions,” write the authors.

• • • A second study, reported in Nature Communications (de Streel G et al. Nat. Comms 2020) demonstrated how selective blockade of the TGF-β1 receptor by regulatory T cells (Tregs) induced regression of mouse tumours otherwise resistant to anti-PD-1 immunotherapy. The blockade was achieved by utilizing antibodies against GARP: TGF- β1complexes. The team, led by Sophie Lucas, from the Université Catholique de Louvain, additionally showed that GARP-expressing Tregs are present in a sizeable subset of human melanoma samples. “Taken together, our results support the clinical evaluation of blocking anti-GARP:TGF-β1 mAbs, administered alone or in combination with other therapeutic strategies, to treat patients with cancer resistant to currently available immunotherapies,” write the authors. A phase I trial (NCT03821935), they add, was recently initiated to test such antibodies in the clinic.

 

Image credit: Alex Ritter, Jennifer Lippincott Schwartz and Gillian Griffiths, National Institutes of Health. Republished under a Creative Commons Licence.

Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Related Topics
  • immune checkpoint blockade (ICB)
  • mouse model
  • responders
  • TGF-β1
  • Treg
Janet Fricker

Janet Fricker is a medical writer specialising in oncology and cardiology. After researching articles for Cancerworld she runs, swims, and eats porridge.

Previous Article
  • Articles
  • Delivery of Care

Raed Al Dieri: Taking pathology from bit part to key player on the European oncology scene

  • 22 September 2020
  • Simon Crompton
View Post
Next Article
  • News

New European Code of Cancer Practice defines patient rights along the cancer pathway

  • 23 September 2020
  • Janet Fricker
View Post
You May Also Like
View Post
  • News

Study highlights need to reanalyse genomics and genetics of metastatic tumours

  • Janet Fricker
  • 27 January 2023
View Post
  • News

Current cervical cancer screening paradigm fails older women

  • Janet Fricker
  • 26 January 2023
View Post
  • News

Call-to-arms for Europe to provide essential paediatric anti-cancer medicines

  • Janet Fricker
  • 9 January 2023
View Post
  • News

Exercise-stimulated myokine production can extend survival in advanced prostate cancer

  • Janet Fricker
  • 9 January 2023
View Post
  • News

Five San Antonio take-aways to improve care of breast cancer patients

  • Janet Fricker
  • 16 December 2022
View Post
  • News

Repurposed drug combination reduces risk of recurrence following surgery for colorectal cancer

  • Janet Fricker
  • 16 December 2022
View Post
  • News

Aerobic activity to outcompete metastasis 

  • Janet Fricker
  • 2 December 2022
View Post
  • News

Ending cancer inequalities: European summit showcases new tools to inform policy

  • Anna Wagstaff
  • 30 November 2022

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

search
or search in Cancerworld archive
Newsletter

Subscribe free to
Cancerworld!

We'll keep you informed of the latest features and news with a fortnightly email

Subscribe now
Latest News
  • Study highlights need to reanalyse genomics and genetics of metastatic tumours
    • 27 January 2023
  • Current cervical cancer screening paradigm fails older women
    • 26 January 2023
  • Call-to-arms for Europe to provide essential paediatric anti-cancer medicines
    • 9 January 2023
  • Exercise-stimulated myokine production can extend survival in advanced prostate cancer
    • 9 January 2023
  • Five San Antonio take-aways to improve care of breast cancer patients
    • 16 December 2022
Article
  • The cancer patients still struggling to access drugs in the wake of anti-corruption reforms
    • 27 January 2023
  • Immunotherapy: outcomes of ultra low-dose trial offer hope for better global access
    • 26 January 2023
  • Cervical cancer elimination efforts boosted by simpler ways to identify and treat pre-cancerous lesions
    • 12 January 2023
Latest printed issue
Social

Would you follow us ?

Contents
  • AI in Genomics and Reporting for Clinical Practice
    • 26 January 2023
  • Telemedicine in Cancer Care: Monitoring, Follow-Up,Tele-Rehabilitation, Palliative and Supportive Care
    • 23 January 2023
  • AI application in diagnosis
    • 11 January 2023
MENU
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
Cancerworld Magazine
  • About the Magazine
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy

Cancerworld is funded by SPCC Sharing Progress in Cancer Care | Via Vincenzo Vela 6, 6500 Bellinzona - Switzerland | info@spcc.net

Archivio Cancerworld

Input your search keywords and press Enter.